Brigatinib 180 mg (Briganix) is a targeted oral anticancer medicine containing Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor. It is primarily used in the treatment of ALK-positive non-small cell lung cancer (NSCLC), particularly in patients whose disease has progressed on or is intolerant to prior ALK inhibitor therapy such as crizotinib. Brigatinib is known for its strong efficacy against a broad range of ALK resistance mutations and its ability to penetrate the central nervous system.

Brigatinib works by selectively inhibiting ALK and related signaling pathways that are responsible for tumor cell growth and survival. By blocking these abnormal signals, Brigatinib helps slow disease progression, reduce tumor burden, and improve clinical outcomes in patients with ALK-positive NSCLC.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Brigatinib 180 mg is indicated for:

• Treatment of adult patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.

• May also be used as a treatment option in ALK-positive NSCLC as per physician discretion and evolving clinical guidelines.

Therapeutic Class

• Antineoplastic Agent

• Tyrosine Kinase Inhibitor (ALK Inhibitor)

Pharmacology

Brigatinib is a potent and selective inhibitor of ALK and several ALK mutant variants associated with resistance to earlier therapies. It inhibits downstream signaling pathways such as PI3K/AKT and MAPK, leading to reduced cancer cell proliferation and increased apoptosis. Brigatinib demonstrates significant activity against intracranial metastases due to its effective central nervous system penetration.

The drug is well absorbed following oral administration, with steady-state concentrations achieved after consistent dosing. Its pharmacokinetic profile supports once-daily dosing.

Dosage and Administration

• Treatment is typically initiated with a lower dose for the first 7 days, followed by escalation to 180 mg once daily, or as prescribed by the physician.

• Brigatinib should be taken orally, with or without food.

• Dose adjustments may be required based on tolerability, adverse reactions, or patient-specific factors.

Key Benefits

• Highly effective against ALK-positive NSCLC, including resistant mutations.

• Demonstrates strong activity against brain metastases.

• Convenient once-daily oral dosing.

• Provides durable disease control and improved progression-free survival.

Precautions and Warnings

• Early pulmonary symptoms such as shortness of breath or cough may occur, especially during initial treatment.

• Monitor blood pressure, heart rate, liver function, and blood glucose regularly.

• Use with caution in patients with pre-existing lung disease, hypertension, or hepatic impairment.

• Pregnancy and breastfeeding should be avoided during treatment.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Adverse Effects

Common adverse effects include nausea, diarrhea, fatigue, headache, cough, increased blood pressure, elevated liver enzymes, and muscle pain. Most side effects are manageable with dose modification and supportive care.

Storage

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.

Brigatinib 180 mg (Briganix) represents an advanced targeted therapy option for ALK-positive NSCLC, offering potent efficacy, central nervous system activity, and improved treatment outcomes for patients with advanced lung cancer.